Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,980,368
  • Shares Outstanding, K 401,528
  • Annual Sales, $ 803,400 K
  • Annual Income, $ -747,060 K
  • 60-Month Beta 1.48
  • Price/Sales 101.19
  • Price/Cash Flow N/A
  • Price/Book 20.65
Trade MRNA with:

Options Overview

Details
  • Implied Volatility 55.32%
  • Historical Volatility 47.37%
  • IV Percentile 4%
  • IV Rank 4.25%
  • IV High 131.61% on 12/01/20
  • IV Low 51.93% on 06/08/21
  • Put/Call Vol Ratio 0.94
  • Today's Volume 46,101
  • Volume Avg (30-Day) 53,553
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 476,127
  • Open Int (30-Day) 427,732

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 6.35
  • Number of Estimates 7
  • High Estimate 8.23
  • Low Estimate 3.27
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +2,148.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
154.51 +28.92%
on 05/19/21
227.71 -12.52%
on 06/07/21
+39.66 (+24.86%)
since 05/18/21
3-Month
117.34 +69.75%
on 03/30/21
227.71 -12.52%
on 06/07/21
+57.73 (+40.81%)
since 03/18/21
52-Week
54.21 +267.44%
on 09/08/20
227.71 -12.52%
on 06/07/21
+134.24 (+206.68%)
since 06/18/20

Most Recent Stories

More News
Dow has Worst Week of the Year on Rate Hike Fears

Dow has Worst Week of the Year on Rate Hike Fears

IBB : 158.77 (-0.18%)
IBBQ : 25.07 (-0.36%)
AMGN : 238.68 (-0.86%)
GILD : 66.61 (-0.91%)
MRNA : 199.19 (-1.62%)
BIIB : 388.44 (+1.28%)
SHOP : 1,466.87 (+1.21%)
SWBI : 23.35 (+17.22%)
CUTR : 47.01 (-0.13%)
Moderna Reaffirms Commitment to Job Creation in Massachusetts

--Company has nearly doubled the size of its workforce since March 31, 2020 and continues to grow

MRNA : 199.19 (-1.62%)
Ocugen (OCGN) Selects Coronavirus Vaccine Manufacturer in US

Ocugen (OCGN) selects Jubilant HollisterStier as its manufacturing partner for its COVID-19 vaccine candidate, Covaxin, in the United States and Canada.

JNJ : 161.98 (-1.96%)
MRNA : 199.19 (-1.62%)
OCGN : 6.57 (+0.46%)
BNTX : 212.42 (-0.83%)
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

Moderna (MRNA) closed at $197.84 in the latest trading session, marking a -1.86% move from the prior day.

MRNA : 199.19 (-1.62%)
Should You Buy Biotech ETFs Now?

Biotech stocks are rallying this month; can the trend continue?

BIIB : 388.44 (+1.28%)
AMGN : 238.68 (-0.86%)
GILD : 66.61 (-0.91%)
MRNA : 199.19 (-1.62%)
IBB : 158.77 (-0.18%)
INO : 8.49 (-3.74%)
XBI : 133.58 (-0.60%)
CLOV : 12.04 (-4.14%)
IBBQ : 25.07 (-0.36%)
U.S. Government Purchases Additional 200 Million Doses of Moderna's COVID-19 Vaccine

--Additional doses will ensure the U.S. government continues to receive the Moderna COVID-19 Vaccine through the first quarter of 2022

MRNA : 199.19 (-1.62%)
Novavax's (NVAX) COVID-19 Vaccine Shows 90% Efficacy in US Study

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.

JNJ : 161.98 (-1.96%)
MRNA : 199.19 (-1.62%)
NVAX : 174.41 (-3.05%)
BNTX : 212.42 (-0.83%)
Moderna and Magenta Partner to Distribute Moderna's COVID-19 Vaccine and Updated Variant Booster Candidates in United Arab Emirates

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Magenta Investments, a leading pharmaceutical and healthcare company that is part of...

MRNA : 199.19 (-1.62%)
Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that , M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and...

DNLI : 73.73 (-1.44%)
MRNA : 199.19 (-1.62%)
RUBY : 25.20 (-0.51%)
SANA : 22.50 (-1.53%)
MCRB : 21.83 (+4.45%)
Rafael Holdings Appoints Three Highly Experienced Biopharmaceutical Leaders to its Board of Directors

/PRNewswire/ -- ., (NYSE: RFL), a pharmaceutical company focused on developing novel cancer metabolism therapeutics, today announced the appointment of three senior biopharmaceutical leaders to its Board...

MRNA : 199.19 (-1.62%)
GILD : 66.61 (-0.91%)
RFL : 43.82 (-5.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA-...

See More

Key Turning Points

3rd Resistance Point 214.85
2nd Resistance Point 209.84
1st Resistance Point 204.52
Last Price 199.19
1st Support Level 194.19
2nd Support Level 189.18
3rd Support Level 183.86

See More

52-Week High 227.71
Last Price 199.19
Fibonacci 61.8% 161.43
Fibonacci 50% 140.96
Fibonacci 38.2% 120.49
52-Week Low 54.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar